Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1944 1
1945 1
1952 2
1953 2
1954 2
1956 1
1959 2
1961 1
1962 2
1964 1
1965 2
1966 4
1967 4
1968 2
1969 3
1971 3
1972 2
1973 5
1974 1
1975 3
1976 2
1977 3
1978 7
1979 10
1980 6
1981 5
1982 4
1983 1
1984 7
1985 4
1986 3
1987 4
1988 14
1989 8
1990 6
1991 7
1992 4
1993 13
1994 15
1995 15
1996 21
1997 13
1998 16
1999 27
2000 34
2001 38
2002 22
2003 44
2004 47
2005 45
2006 49
2007 61
2008 72
2009 90
2010 103
2011 107
2012 111
2013 139
2014 137
2015 134
2016 156
2017 159
2018 178
2019 198
2020 296
2021 367
2022 376
2023 354
2024 330
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,505 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ahmad n
Search for Ahamd N instead (3 results)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Among authors: ahmad nn. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Lan Z, et al. Among authors: ahmad n. Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17. Lancet Respir Med. 2020. PMID: 32192585 Free PMC article.
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, Hemmingway A, Ahmad NN, Bunck MC, Stefanski A. de Lemos JA, et al. Among authors: ahmad nn. Hypertension. 2024 Apr;81(4):e41-e43. doi: 10.1161/HYPERTENSIONAHA.123.22022. Epub 2024 Feb 5. Hypertension. 2024. PMID: 38314555 Free PMC article. No abstract available.
Health effects associated with exposure to secondhand smoke: a Burden of Proof study.
Flor LS, Anderson JA, Ahmad N, Aravkin A, Carr S, Dai X, Gil GF, Hay SI, Malloy MJ, McLaughlin SA, Mullany EC, Murray CJL, O'Connell EM, Okereke C, Sorensen RJD, Whisnant J, Zheng P, Gakidou E. Flor LS, et al. Among authors: ahmad n. Nat Med. 2024 Jan;30(1):149-167. doi: 10.1038/s41591-023-02743-4. Epub 2024 Jan 9. Nat Med. 2024. PMID: 38195750 Free PMC article.
PLK1 inhibition-based combination therapies for cancer management.
Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. Su S, et al. Among authors: ahmad n. Transl Oncol. 2022 Feb;16:101332. doi: 10.1016/j.tranon.2021.101332. Epub 2021 Dec 29. Transl Oncol. 2022. PMID: 34973570 Free PMC article. Review.
3,505 results